Weei-Chin Lin is an Oncology physician affiliated with Baylor College of Medicine. OpenAlex indexes 51 publications with 6,409 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Imbruvica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Targeting Convergent Pathways to Overcome Osimertinib Resistance in EGFR-Mutated Lung Cancer
Baylor College of Medicine
FY2026$411,400R21CA312323 - Novel therapeutics for targeting checkpoint dysfunction in cancer
Baylor College of Medicine
FY2026$382,469R01CA203824
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors
Proceedings of the National Academy of Sciences
2023 - DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
Cancer Research Communications
2023 - 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer
Proceedings of the National Academy of Sciences
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Christie Ballantyne, MD
Baylor College of Medicine
Biykem Bozkurt, MD
Baylor College of Medicine
Malcolm Brenner, MD
Baylor College of Medicine
Sankar Navaneethan, MD
Baylor College of Medicine
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”